TOT BIOPHARM International Company Limited
HKEX:1875.HK
2 (HKD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 780.629 | 442.178 | 76.325 | 22.491 | 45.308 | 39.219 | 51.608 |
| Cost of Revenue
| 206.643 | 71.563 | 48.851 | 6.961 | 11.316 | 5.98 | 4.242 |
| Gross Profit
| 573.986 | 370.615 | 27.474 | 15.53 | 33.992 | 33.239 | 47.366 |
| Gross Profit Ratio
| 0.735 | 0.838 | 0.36 | 0.69 | 0.75 | 0.848 | 0.918 |
| Reseach & Development Expenses
| 103.89 | 151.168 | 214.699 | 235.196 | 191.078 | 188.651 | 105.935 |
| General & Administrative Expenses
| 68.31 | 62.587 | 56.336 | 46.855 | 95.091 | 31.208 | 9.172 |
| Selling & Marketing Expenses
| 441.019 | 203.954 | 22.849 | 25.953 | 31.544 | 38.935 | 28.886 |
| SG&A
| 509.329 | 266.541 | 79.185 | 72.808 | 126.635 | 70.143 | 38.058 |
| Other Expenses
| 0.09 | 0.5 | 0.262 | 0.394 | -12.224 | 11.054 | 9.723 |
| Operating Expenses
| 595.433 | 409.449 | 282.928 | 305.268 | 305.489 | 269.848 | 153.716 |
| Operating Income
| -33.06 | -39.076 | -259.7 | -288.672 | -271.497 | -237.177 | -105.969 |
| Operating Income Ratio
| -0.042 | -0.088 | -3.403 | -12.835 | -5.992 | -6.048 | -2.053 |
| Total Other Income Expenses Net
| -4.696 | -11.115 | -5.759 | 2.929 | -27.803 | -31.654 | -42.337 |
| Income Before Tax
| -37.756 | -50.046 | -261.216 | -288.498 | -299.3 | -268.263 | -148.687 |
| Income Before Tax Ratio
| -0.048 | -0.113 | -3.422 | -12.827 | -6.606 | -6.84 | -2.881 |
| Income Tax Expense
| 0.001 | -2.599 | 2.461 | 4.287 | 31.879 | -29.25 | 0.088 |
| Net Income
| -37.757 | -49.916 | -261.216 | -288.498 | -331.179 | -268.263 | -148.687 |
| Net Income Ratio
| -0.048 | -0.113 | -3.422 | -12.827 | -7.31 | -6.84 | -2.881 |
| EPS
| -0.052 | -0.078 | -0.46 | -0.51 | -0.99 | -0.47 | -0.26 |
| EPS Diluted
| -0.052 | -0.078 | -0.46 | -0.51 | -0.99 | -0.47 | -0.26 |
| EBITDA
| 24.411 | -3.361 | -218.759 | -255.058 | -240.07 | -221.417 | -92.768 |
| EBITDA Ratio
| 0.031 | -0.008 | -2.866 | -11.34 | -5.299 | -5.646 | -1.798 |